Company news
Q32 Bio Inc. news in 2023
Q32 Bio Inc.'s news releases, calls and decks from 2023, newest first.
Q32 Bio and Homology Medicines Announce Merger Agreement
November 15, 2023
Homology Medicines Reports Third Quarter 2023 Financial Results
November 13, 2023
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
August 13, 2023
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
July 26, 2023
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
July 26, 2023
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
May 15, 2023
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
May 10, 2023
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
May 2, 2023
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
March 14, 2023
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 8, 2023
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
March 8, 2023
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
March 1, 2023
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting
February 21, 2023
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
January 3, 2023
Decks in 2023
- Homology Medicines — Merger or Acquisition (November 2023)
Merger or acquisition · 41 slides · Nov 16, 2023